October 2025 UPMC for You and UPMC Community HealthChoices formulary update

Oct. 2025Pharmacy Updates

Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.

There are covered alternatives that may be an option for your patients, depending on their health needs.

Tretinoin cream is a covered alternative for Retin-A (cream, gel).

Covered alternatives for Xifaxan include loperamide capsule, dicyclomine (10 mg capsule, 20 mg tablet), lactulose solution, and azithromycin. Coverage is available for Xifaxan 200 mg tablet for a diagnosis of hepatic encephalopathy only and a prior authorization is required. The dose and duration of therapy for Xifaxan 200 mg tablet must be consistent with nationally recognized compendia or peer-reviewed literature.

Xifaxan coverage update

Coverage of Xifaxan tablet, including both the 200 mg and 550 mg strengths, is no longer available under UPMC for You and UPMC Community HealthChoices.

The manufacturer of Xifaxan may provide the drug to Medicaid patients at no cost through its patient assistance program. The program application is available by phone at 1-833-862-8727 or online at bauschhealthpap.com.

Recent Announcements

Medicaid Renewal

 Starting in 2027, some Medicaid recipients (ages 19–-64) will have new requirements to keep their coverage.
Aug. 2026Important Notices

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Aug. 2026Important Notices

Voluntary nationwide recall: Tyenne (Fresenius – August 2026)

Fresenius Kabi is recalling one lot, lot 16UI07, of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials. Tyenne is used for the treatment of certain arthritis conditions.
Aug. 2026Pharmacy Updates